Leo Chen is a Manager in Value and Evidence for Genitourinary Cancers at Pfizer, where they support global projects for the launch of Sasanlimab, Mevrometostat, and Talzenna. They possess a strong background in Global Health Economics and Outcomes Research (HEOR) and Market Access, having previously worked as a Global HEOR Research Associate focusing on Inflammation and Immunology Pipeline and Rare Diseases. Leo earned a Master of Public Health from Columbia University and a Bachelor of Science in Biology with a minor in Economics from Emory University. Their diverse experience includes roles at Columbia University Mailman School of Public Health and National Taiwan University Hospital, enhancing their expertise in health policy and research.
This person is not in the org chart
This person is not in any teams
This person is not in any offices